Online Exercise Program for Transplant Patients: A Pilot Study
NCT07923188, Not applicable, Enrolling by invitation, Cardenal Herrera University
Trial 10
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | Online Exercise Program for Transplant Patients: A Pilot Study | ClinicalTrials.gov |
| NCT number | NCT07923188 | ClinicalTrials.gov |
| Status | Enrolling by invitation | ClinicalTrials.gov |
| Phases | Not applicable | ClinicalTrials.gov |
| Enrollment | 20 participants, estimated | ClinicalTrials.gov |
| Lead sponsor | Cardenal Herrera University | ClinicalTrials.gov |
| Conditions | Kidney Transplantation, Physical Function, Muscle Weakness Condition, Physical Activity | ClinicalTrials.gov |
| Interventions | Online Therapeutic Exercise Programme, Usual Care Control Group | ClinicalTrials.gov |
| First posted | 2026-11-06 | ClinicalTrials.gov |
| Last updated | 2026-11-06 | ClinicalTrials.gov |
Registered outcomes 29
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Recruitment Rate | During the recruitment period, up to 2 months | The percentage of eligible individuals who are enrolled in the study. | ClinicalTrials.gov |
| Primary | Adherence to the Online Exercise Programme | Throughout the 24-week intervention | Adherence will be calculated as the percentage of exercise sessions completed by each participant relative to the total number of sessions scheduled during the 24-week intervention. | ClinicalTrials.gov |
| Primary | Participant Retention Rate | At 24 weeks | The percentage of enrolled participants who complete the final study assessment relative to the total number of participants initially enrolled. | ClinicalTrials.gov |
| Primary | Number of Adverse Events During the Exercise Programme | Throughout the 24-week intervention | Safety will be assessed by recording adverse events occurring during exercise sessions, including musculoskeletal injuries, cardiovascular symptoms, exercise intolerance, or any event requiring modification or temporary suspension of the intervention. | ClinicalTrials.gov |
| Secondary | Lower-Limb Muscle Strength Assessed by Hand-Held Dynamometry | Baseline, 4 weeks, 3 months, and 6 months | Maximal isometric strength of the hip flexors and hip abductors will be assessed using hand-held dynamometry. Three maximal voluntary contractions will be performed for each muscle group, and the maximum value will be recorded in kilogram-force (kgf). | ClinicalTrials.gov |
| Secondary | Handgrip Strength | Baseline, 3 months, and 6 months | Handgrip strength will be assessed using a Jamar® hydraulic dynamometer. Three maximal voluntary contractions will be performed with each hand, and the maximum value will be recorded in kilograms (kg). | ClinicalTrials.gov |
| Secondary | 60-Second Sit-to-Stand Test Performance | Baseline, 3 months, and 6 months | Functional capacity will be assessed using the 60-Second Sit-to-Stand Test (STS-60). The total number of complete sit-to-stand repetitions performed within 60 seconds will be recorded. A higher number of repetitions indicates better functional performance. | ClinicalTrials.gov |
| Secondary | Timed Up and Go Test Performance | Baseline, 3 months, and 6 months | Functional mobility and dynamic balance will be assessed using the Timed Up and Go (TUG) test. The time required to stand from a chair, walk 3 metres, turn, return, and sit down will be recorded in seconds. | ClinicalTrials.gov |
| Secondary | 6-Minute Walk Test Distance | Baseline, 3 months, and 6 months | Walking capacity will be assessed using the 6-Minute Walk Test (6MWT). The total distance walked during 6 minutes will be recorded in metres (m). | ClinicalTrials.gov |
| Secondary | Physical Activity Assessed by the Human Activity Profile | Baseline, 3 months, and 6 months | Physical activity will be assessed using the Human Activity Profile (HAP). The Adjusted Activity Score (AAS) will be recorded. | ClinicalTrials.gov |
| Secondary | Change in Risk of Sarcopenia Assessed by SARC-F | Baseline, 3 months, and 6 months | Risk of sarcopenia will be assessed using the SARC-F questionnaire. The total score ranges from 0 to 10, with a score ≥4 indicating risk of sarcopenia. | ClinicalTrials.gov |
| Secondary | Frailty Assessed by the FRAIL Scale | Baseline, 3 months, and 6 months | Frailty will be assessed using the FRAIL scale. Scores range from 0 to 5, with a score ≥3 indicating frailty. | ClinicalTrials.gov |
| Secondary | Rectus Femoris Muscle Characteristics Assessed by Ultrasound | Baseline, 3 months, and 6 months | Musculoskeletal ultrasound will be used to assess rectus femoris muscle thickness (mm), cross-sectional area (cm²), and muscle echogenicity. | ClinicalTrials.gov |
| Secondary | Anthropometric Measurements | Baseline, 3 months, and 6 months | Waist circumference, upper-arm circumference, and calf circumference will be measured using standardised procedures and recorded in centimetres (cm). | ClinicalTrials.gov |
| Secondary | Body Composition Assessed by Bioelectrical Impedance Vector Analysis | Baseline, 3 months, and 6 months | Body composition will be assessed using bioelectrical impedance vector analysis (BIVA), including muscle mass. | ClinicalTrials.gov |
| Secondary | T3 | Baseline, 3 months, and 6 months | Triiodothyronine (T3) is the primary biologically active form of thyroid signaling molecules. Measures both bound and free T3 combined. (ng/dL) | ClinicalTrials.gov |
| Secondary | T4 | Baseline, 3 months, and 6 months | Thyroxine (T4) is one of the two main hormones produced by the thyroid gland.(mcg/dL) | ClinicalTrials.gov |
| Secondary | Testosterone | Baseline, 3 months, and 6 months | Testosterone is the primary male sex hormone (androgen), although it is also present and essential in females in much smaller amounts. It is a steroid hormone synthesized primarily from cholesterol; (ng/dL :nanograms per deciliter) | ClinicalTrials.gov |
| Secondary | Cortisol | Baseline, 3 months, and 6 months | Cortisol is a steroid hormone produced by the adrenal glands (located on top of each kidney) that is essential for life and regulates a wide range of vital processes throughout the body. | ClinicalTrials.gov |
| Secondary | Estrogens | Baseline, 3 months, and 6 months | Estrogens are a group of hormones crucial for sexual and reproductive development, primarily in women.Estrogen levels are typically measured via a blood test and reported in picograms per milliliter (pg/mL) or picomoles per liter (pmol/L). | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 4
The papers the trial lists on ClinicalTrials.gov.
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)